Trevena Attends National Institutes of Health Meeting to Discuss Development of Novel, Improved Pain Medications
June 20 2017 - 4:01PM
Trevena, Inc. (NASDAQ:TRVN) today announced its recent
participation in the “Cutting Edge Science Meeting Series to End
the Opioid Crisis: Development of Safe, Effective, Non-Addictive
Pain Treatments” conference, held June 16, 2017 at the National
Institutes of Health (NIH) Campus, Bethesda, MD. The conference
gathered leading scientists and physicians from academia, industry,
and government to discuss how new approaches to pain management
might reduce risks to patients and communities who have suffered
from the opioid crisis while improving treatment options for
serious pain. David Soergel, M.D., Trevena’s chief medical officer,
participated in the conference.
“The opioid crisis compels us as scientists and clinicians to
evaluate new methods for managing pain more safely and with less
risk of abuse and dependence,” said Dr. Soergel. “We cannot ignore
patients’ pain, but we cannot accept the status quo. I’m pleased
Trevena was asked to participate in the much-needed discussion
sponsored by the NIH of how we can accelerate basic research and
drug development to tackle the challenges of pain management. These
include finding novel non-opioid mechanisms for treating pain, but
also finding safer opioids for patients who still require opioid
analgesia. Trevena is proud to play a role in these important
efforts.”
Among the approaches discussed at the conference were biased
ligands, which target drug receptors with a novel mechanism to
selectively activate therapeutic responses while reducing adverse
effects. Trevena has discovered new biased ligands for acute
pain, chronic pain, and acute migraine, among others. Most notably,
Trevena’s OLINVOTM (oliceridine injection) is a biased ligand
designed to improve safety of mu-opioid-receptor mediated pain
relief and is in Phase 3 development for the management of moderate
to severe acute pain in patients who require an intravenous opioid
in hospitals and similar settings.
About moderate-to-severe acute pain management in
hospitals
Pain management is essential for patient recovery and discharge
from hospitals and ambulatory surgery centers. Despite the use of
other approaches to pain relief, IV opioids often remain necessary
for treating moderate-to-severe acute pain: approximately 50
million hospital patients in the U.S. are treated each year with
conventional IV opioids. However, these medications are associated
with important adverse effects: nausea and vomiting occur in
approximately 30% of postoperative patients and contribute
approximately $1 billion in U.S. hospital costs; opioid-induced
respiratory depression can threaten patient safety and accounts for
up to $28,000 in additional hospital costs per patient. This unmet
need is highest for patients whose pain management requires an IV
opioid but are at risk from opioid-induced respiratory depression,
may suffer surgical complications from post-operative vomiting, or
whose recovery may be prolonged by post-operative nausea and
vomiting.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing
innovative therapies based on breakthrough science to benefit
patients and healthcare providers confronting serious medical
conditions. The Company’s lead program is OLINVOTM (oliceridine
injection), which has completed two successful Phase 3 trials for
the management of moderate-to-severe acute pain. Trevena has
discovered four novel and differentiated drug candidates, including
OLINVO. Trevena also has discovered TRV250, in early clinical
development for the treatment of acute migraine. The Company
maintains an early stage portfolio of drug discovery programs.
Contacts
Investors:
Jonathan Violin, Ph.D.
Vice President, Corporate Strategy & Investor Relations
610-354-8840 x231
jviolin@trevena.com
Media:
Public Relations
PR@trevena.com
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024